Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug

6-Diazo-5-oxo-l-norleucine (DON) is a glutamine antagonist that suppresses cancer cell metabolism but concurrently enhances the metabolic fitness of tumor CD8(+) T cells. DON showed promising efficacy in clinical trials; however, its development was halted by dose-limiting gastrointestinal (GI) toxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rais, Rana, Lemberg, Kathryn M., Tenora, Lukáš, Arwood, Matthew L., Pal, Arindom, Alt, Jesse, Wu, Ying, Lam, Jenny, Aguilar, Joanna Marie H., Zhao, Liang, Peters, Diane E., Tallon, Carolyn, Pandey, Rajeev, Thomas, Ajit G., Dash, Ranjeet P., Seiwert, Tanguy, Majer, Pavel, Leone, Robert D., Powell, Jonathan D., Slusher, Barbara S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668306/
https://www.ncbi.nlm.nih.gov/pubmed/36383674
http://dx.doi.org/10.1126/sciadv.abq5925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668306/
https://www.ncbi.nlm.nih.gov/pubmed/36383674
http://dx.doi.org/10.1126/sciadv.abq5925

Ejemplares similares